Vertex Initiates First Phase 3 Study of VX-659, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it is initiating the first Phase 3 study of VX-659, tezacaftor and ivacaftor as an investigational triple combination regimen for people with cystic fibrosis (CF) who have one F508del mutation and one minimal function mutation. The study will enroll 360 patients, and the primary endpoint of the study is the mean absolute change from baseline in percent predicted forced expiratory volume in one second (ppFEV1) at week four of treatment. The study is designed to support the submission of a New Drug Application (NDA) in the U.S. using data from the 4-week primary efficacy endpoint together with safety data through 12 weeks of treatment.
“Our goal is to bring the best triple combination to patients as rapidly as possible, and this first Phase 3 study of VX-659 in combination with tezacaftor and ivacaftor is a significant step toward that goal,” said Jeffrey Chodakewitz, M.D., Executive Vice President and Chief Medical Officer at Vertex. “We’re pleased to initiate this study and look forward to working closely with the CF community to advance our two different triple combination regimens through Phase 3 development.”
“There is a significant unmet medical need to treat the underlying cause of CF for those with one F508del mutation and a minimal function mutation, and these patients are eagerly awaiting new treatment options,” said Steven M. Rowe, M.D., M.S.P.H., Director of the Gregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham, and co-chair of Vertex's Triple Combination Steering Committee. “The Phase 2 data for the triple combination of VX-659, tezacaftor and ivacaftor showed impressive improvements in multiple measures of CF for patients with minimal function mutations, and I am pleased that this Phase 3 study is designed to enable rapid advancement of the VX-659 regimen toward patients.”
About the Phase 3 Study
The randomized, double-blind, placebo-controlled Phase 3 study will evaluate VX-659 in combination with tezacaftor and ivacaftor, or triple placebo, in approximately 360 patients ages 12 and older who have one F508del mutation and one minimal function mutation. A list of the minimal function mutations currently included in this study can be found here. The primary endpoint of the study is the mean absolute change in lung function (ppFEV1) from baseline at week four of triple combination treatment compared to placebo.
The study is designed to support the submission of an NDA to the U.S. Food and Drug Administration (FDA) based on data from the 4-week primary efficacy analysis and on safety data through 12 weeks of treatment. The study will evaluate VX-659 in combination with tezacaftor and ivacaftor for a total of 24 weeks of treatment to generate additional safety data and data for key secondary endpoints, including the number of pulmonary exacerbations, change in body mass index, change in sweat chloride, and changes in patient-reported outcomes as measured by the respiratory domain of the Cystic Fibrosis Questionnaire-Revised (CFQ-R), among others. The 24-week data from this study are not required to complete the NDA submission. Data from this study will also be used to support planned regulatory submissions in Europe and other regions.
The study will evaluate a fixed-dose combination of VX-659 (240 mg), tezacaftor (100 mg) and ivacaftor (150 mg) in the morning followed by ivacaftor (150 mg) in the evening. An open-label extension study will be conducted where all eligible patients, including those who received placebo, will receive the triple combination regimen for up to an additional 96 weeks.
Vertex plans to initiate multiple additional Phase 3 studies of VX-659 and VX-445 triple combination regimens in 2018. Regulatory discussions are ongoing regarding the design of these additional Phase 3 studies.
CF is a rare, life-shortening genetic disease affecting approximately 75,000 people in North America, Europe and Australia.
CF is caused by a defective or missing CFTR protein resulting from mutations in the CFTR gene. Children must inherit two defective CFTR genes — one from each parent — to have CF. There are approximately 2,000 known mutations in the CFTR gene. Some of these mutations, which can be determined by a genetic test, or genotyping test, lead to CF by creating non-working or too few CFTR proteins at the cell surface. The defective function or absence of CFTR protein results in poor flow of salt and water into and out of the cell in a number of organs. In the lungs, this leads to the buildup of abnormally thick, sticky mucus that can cause chronic lung infections and progressive lung damage in many patients that eventually leads to death. The median age of death is in the mid-to-late 20s.
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases.
Founded in 1989 in Cambridge, Mass., Vertex's headquarters is now located in Boston's Innovation District. Today, the company has research and development sites and commercial offices in the United States, Europe, Canada and Australia. Vertex is consistently recognized as one of the industry's top places to work, including being named to Science magazine's Top Employers in the life sciences ranking for eight years in a row. For additional information and the latest updates from the company, please visit www.vrtx.com.
Collaborative History with Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT)
Vertex initiated its CF research program in 2000 as part of a collaboration with CFFT, the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation. KALYDECO® (ivacaftor), ORKAMBI® (lumacaftor/ivacaftor), SYMDEKO™ (tezacaftor/ivacaftor and ivacaftor), VX-440, VX-152, VX-659 and VX-445 were discovered by Vertex as part of this collaboration.
Special Note Regarding Forward-looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, Dr. Chodakewitz's and Dr. Rowe’s statements in the second and third paragraphs, respectively, and the information provided regarding the (i) timing and design of the Phase 3 study of VX-659, tezacaftor and ivacaftor, (ii) potential to submit an NDA to the U.S. FDA based on data from the initiated Phase 3 study and (iii) timing and plans to initiate additional Phase 3 studies of triple combination regimens containing VX-659 and/or VX-445. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release, and there are a number of factors that could cause actual events or results to differ materially from those indicated by such forward-looking statements. Those risks and uncertainties include that data from the Phase 3 development programs may not support continued development or approval of the company's triple-combination regimens due to safety, efficacy or other reasons, and other risks listed under Risk Factors in Vertex's annual report and quarterly reports filed with the Securities and Exchange Commission and available through the company's website at www.vrtx.com. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.
Vertex Pharmaceuticals Incorporated
Michael Partridge, 617-341-6108
Eric Rojas, 617-961-7205
Zach Barber, 617-341-6470
Megan Goulart, + 1-617-341-6992
Europe & Australia:
Rebecca Hunt, +44 7718 962 690
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Skitude Premium Launches, Offering Personalised 3D Mapping, 3D Tracks, Advanced Statistics, Speed Heat Maps and Apple Watch Compatibility18.12.2018 18:58 | Tiedote
Skitude, the world’s largest apps community of digitally-connected snow sport lovers, with over a million users, has launched a premium version of its popular profile. Skitude apps are available for Android and Apple devices, and the premium upgrade offers the option to see your day’s skiing/boarding as an interactive 3D map, a speed ‘heat map’ or by statistical analysis of descents, slopes and distances covered. There is also Apple Watch compatibility, so your smartphone battery won’t be dead by lunchtime, as can often be the case with tracking apps. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181218005591/en/ (Photo: Skitude) Premium also offers 3D maps and advanced statistics for over 2,500 resorts worldwide, with real time information on slope conditions and whether runs are open. There are ‘points of interest’, webcams and a wealth of other useful information to help you make the most of your time on the slopes. Skit
Five New Consumer Wearable Products Powered by Movesense to be Showcased at CES 201918.12.2018 18:32 | Tiedote
Five companies launching new wearable devices that provide more targeted, accurate, and consistent data for consumers tracking health, athletic performance, stress, and more will exhibit in one place at the International Consumer Electronics Show (CES) 2019, held from January 8-11, 2019. The products rely on Movesense’s motion sensing technology and sensor platform to improve athletic training, avoid costly medical interventions in elderly patients, and manage stress for people in demanding occupations. These new devices will be on display at the Movesense-Suunto booth, #44537. “We were one of nine companies selected to take part in 1st and Future, a sports tech pitch contest sponsored by the NFL,” said David Troup, founder of Konect Sports. “We went from that pitch to a product in 10 months. While developing our first product, Konect Speed Training, we conceived of a second product, the Konect Speed Pro, which we developed in seven weeks. We could not have done this without Movesense.
PSB Names Mike Chuter Chief Executive Officer18.12.2018 17:15 | Tiedote
PSB, a global research-based consultancy within BCW, announced today that Mike Chuter has joined the firm as Chief Executive Officer, effective immediately. Chuter is based in New York and reports to Donna Imperato, Global CEO of BCW. He is responsible for the global growth and development of the organization across its Corporate, Political, Media and Entertainment practices. “Mike is exceptionally well-suited to lead PSB given his deep experience interpreting data through both analytical and creative lenses and in driving integrated communications programs rooted in analytics,” said Imperato. “Mike is the right person to help PSB advise on holistic creative communications solutions that leverage the firm’s industry-leading expertise in primary research and behavioral, social and other third-party data analysis.” Chuter is a 25-year agency veteran who joins PSB from global social impact organization Thankful, which he co-founded in 2013, a one-half commercial enterprise, one-half socia
The Keio Plaza Hotel Tama Creates New “Hello Kitty” Photographic Spot and Sanrio Characters Themed Rooms －“My Melody” and “Little Twin Stars”18.12.2018 17:05 | Tiedote
The Keio Plaza Hotel Co., Ltd., one of Japan’s most prestigious hotel companies operating hotels located in the Shinjuku district of Tokyo and other locations, is proud to announce that it is fortifying its collaborative relationship with the Sanrio Co., Ltd. (Headquarters: Shinagawa, Tokyo, President and CEO: Shintaro Tsuji) to expand our facilities and services featuring “Hello Kitty” and other Sanrio characters at our Keio Plaza Hotel Tama facility. We will create a new photographic spot within our hotel lobby where guests can take pictures with “Princess Kitty” in March 2019, and renovate another four rooms to become Sanrio characters themed rooms, two rooms each in the themes of “My Melody” and “Little Twin Stars” (Kiki and Lala), in June 2019 in addition to the four existing “Hello Kitty” themed rooms. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181218005251/en/ In Keio Plaza Hotel Tama, a new photo spot based upon
Tradeshift Acquires Babelway, a Key Innovator of Cloud Integration Technology18.12.2018 16:58 | Tiedote
Tradeshift, the leader in supply chain payments and marketplaces, today announced it has acquired Babelway, a key innovator of cloud integration technology. For years, Babelway has provided a standardized way for the world’s largest businesses to connect disparate systems with ease and speed. Now, the company has joined forces with the world’s largest business commerce platform, enabling any business in the world to connect to digital global trade. Babelway’s powerful technology will now be offered as Tradeshift Link. Tradeshift Link will accelerate the integration of disconnected systems used for B2B buying, paying, and selling, which is a significant challenge for companies building modern, digital supply chains. “We believe that B2B commerce should be connected, digital, and flexible. We’ve been partnering with Babelway for over six years and in that time have seen the massive value their technology provides for our users,” said Christian Lanng, CEO and founder of Tradeshift. “This
Chartbeat Announces the Most Engaging Stories of 201818.12.2018 15:00 | Tiedote
Chartbeat, the leading content intelligence platform for publishers, today announces the Most Engaging Stories of 2018, the articles that were read most this year based on highest Engaged Time. Selected from over 60 million pieces of content published on thousands of media sites around the world, the top stories serve as a snapshot of the year’s major events and highlight the themes that resonated most with readers. 2018 saw familiar political and social themes rise to the top, including Brexit, the Trump administration, the #MeToo movement, and climate change, but it was the deeply investigated and deeply personal stories of human struggle from publications like CNN, The New York Times, New York Magazine, and Rolling Stone that topped the list again this year. “Each year, the Most Engaging Stories list proves the power of storytelling. We learn more about the world, of course, but we also learn more about how to make sense of it and each other,” said John Saroff, CEO of Chartbeat. “Th
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme